Condition: Invasive Mould Infection · Sponsor: Elion Therapeutics, Inc.
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
This description comes directly from the study's public registry record.
Laura A. Navalta · 443-423-1785 · info@eliontx.com
Gordana Schnider, MHA · 443-423-1785 · info@eliontx.com
Always discuss trial participation with your own doctor first.
| U. of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| UC Davis Medical Center | Sacramento, California, United States | Recruiting |
| Augusta University Medical Center | Augusta, Georgia, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| U. of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Washington U. | St Louis, Missouri, United States | Recruiting |
| U. of Texas, MD Anderson | Houston, Texas, United States | Recruiting |
| AZ Sint-Jan Brugge | Bruges, Belgium | Recruiting |
| Universite Libre de Bruxelles (ULB) - Institut Jules Bordet | Brussels, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Juravinski Hospital | Hamilton, Ontario, Canada | Recruiting |
| Centre Hospitalier d'Argenteuil | Argenteuil, France | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07215273